Elicio Therapeutics Inc. has announced updated immunogenicity results from its ongoing Phase 2 AMPLIFY-7P trial of ELI-002 7P, a lymph node-targeted amphiphile therapeutic cancer vaccine for patients with KRAS-mutated pancreatic ductal adenocarcinoma. According to the company, ELI-002 7P induced mKRAS-specific T cell responses in 99% of evaluable patients (89 out of 90), with robust immune responses observed across all seven mKRAS antigens. More than 80% of patients responded to each individual KRAS mutation, and 88% generated responses to their own tumor-specific mutation. Cytotoxic mKRAS-specific T cell responses were induced in 86.8% of patients (66 out of 76), with both CD8+ and CD4+ T cells detected in 75% of cases. The company remains blinded to the clinical efficacy outcomes of the trial. These data will be presented at the Society for Immunotherapy of Cancer $(SITC)$ 2025 Annual Meeting, scheduled for November 7-8, 2025, in National Harbor, MD. Additionally, preclinical data on ELI-004, an intra-tumoral immunotherapy, will also be presented at the meeting.